Terms: = Leukemia AND TRRAP, TR-AP, 8295, ENSG00000196367, Q9Y4A5, PAF400, PAF350/400, FLJ10671, STAF40, Tra1 AND Treatment
1098 results:
1. JAK2 as Predictor of Therapeutic Response in Patients with Chronic Myeloid leukemia Treated with Imatinib.
Wijaya I; Bashari MH; Reniarti L; Rahmawati A; Roesli RMA
Dis Markers; 2024; 2024():2906566. PubMed ID: 38716474
[TBL] [Abstract] [Full Text] [Related]
2. Assessment of the
Nasr GM; Thawabieh OM; Talaat RM; Moawad M; El Hamshary MO
Front Biosci (Landmark Ed); 2024 Apr; 29(4):162. PubMed ID: 38682177
[TBL] [Abstract] [Full Text] [Related]
3. Combination of venetoclax and azacitidine in relapsed/refractory acute B-cell lymphoblastic leukemia: a case series from a single center.
Hao Z; Fei Y; Chen J; Huang S; Wang L; Yu Y; Bian M; Si Y; Zhang X; Yang X; Zhang B; Wan Y; Zhang Y; Lin G
Hematology; 2024 Dec; 29(1):2344998. PubMed ID: 38666535
[TBL] [Abstract] [Full Text] [Related]
4. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial.
Bazinet A; Kantarjian H; Bataller A; Pemmaraju N; Borthakur G; Chien K; Alvarado Y; Bose P; Jabbour E; Yilmaz M; DiNardo C; Issa G; Montalban-Bravo G; Short N; Sasaki K; Bull-Linderman D; Daver N; Garcia-Manero G; Ravandi F; Kadia T
Lancet Haematol; 2024 Apr; 11(4):e287-e298. PubMed ID: 38548404
[TBL] [Abstract] [Full Text] [Related]
5. Pharmacokinetics of PEGasparaginase in Infants with Acute Lymphoblastic leukemia.
Brigitha LJ; Mondelaers V; Liu Y; Albertsen BK; Zalewska-Szewczyk B; Rizzari C; Kotecha RS; Pieters R; Huitema ADR; van der Sluis IM
Pharm Res; 2024 Apr; 41(4):711-720. PubMed ID: 38538970
[TBL] [Abstract] [Full Text] [Related]
6. Venetoclax plus cytarabine and azacitidine in relapsed/refractory AML: An open-label, single-arm, phase 2 study.
You L; Liu Y; Mai W; Xie W; Zhou D; Mao L; Chen L; Zhou X; Ma L; Zheng X; Wei J; Lou Y; Ye X; Tong H; Jin J; Meng H
Eur J Cancer; 2024 May; 202():113979. PubMed ID: 38471289
[TBL] [Abstract] [Full Text] [Related]
7. Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial.
Kater AP; Arslan Ö; Demirkan F; Herishanu Y; Ferhanoglu B; Diaz MG; Leber B; Montillo M; Panayiotidis P; Rossi D; Skarbnik A; Tempescul A; Turgut M; Mellink CH; van der Kevie-Kersemaekers AF; Lanham S; Sale B; Del Rio L; Popovic R; Chyla BJ; Busman T; Komlosi V; Wang X; Sail K; Pena GE; Vizkelety T; Forconi F
Lancet Oncol; 2024 Apr; 25(4):463-473. PubMed ID: 38467131
[TBL] [Abstract] [Full Text] [Related]
8. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study.
Bazinet A; Garcia-Manero G; Short N; Alvarado Y; Bataller A; Abuasab T; Islam R; Montalbano K; Issa G; Maiti A; Yilmaz M; Jain N; Masarova L; Kornblau S; Jabbour E; Montalban-Bravo G; Rausch CR; Pierce S; DiNardo CD; Kadia T; Daver N; Konopleva M; Huang X; Kantarjian H; Ravandi F
Lancet Haematol; 2024 Apr; 11(4):e276-e286. PubMed ID: 38452788
[TBL] [Abstract] [Full Text] [Related]
9. Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European leukemiaNet international registry.
Chelysheva E; Apperley J; Turkina A; Yassin MA; Rea D; Nicolini FE; Barraco D; Kazakbaeva K; Saliev S; Abulafia AS; Al-Kindi S; Byrne J; Robertson HF; Cerrano M; Shmakov R; Polushkina E; de Fabritiis P; Trawinska MM; Abruzzese E
Leukemia; 2024 Apr; 38(4):788-795. PubMed ID: 38388649
[TBL] [Abstract] [Full Text] [Related]
10. [Venetoclax Combined with CACAG Regimen in the treatment of Patients with Refractory/Relapse Acute Myeloid leukemia: A Prospective Clinical Study].
Gao WJ; Yang JJ; Li M; Wen YN; Jiao YF; LE N; Liu YC; Wang N; Huang S; Dou LP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):90-95. PubMed ID: 38387905
[TBL] [Abstract] [Full Text] [Related]
11. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study.
Bataller A; Montalban-Bravo G; Bazinet A; Alvarado Y; Chien K; Venugopal S; Ishizawa J; Hammond D; Swaminathan M; Sasaki K; Issa GC; Short NJ; Masarova L; Daver NG; Kadia TM; Colla S; Qiao W; Huang X; Kanagal-Shamanna R; Hendrickson S; Ravandi F; Jabbour E; Kantarjian H; Garcia-Manero G
Lancet Haematol; 2024 Mar; 11(3):e186-e195. PubMed ID: 38316133
[TBL] [Abstract] [Full Text] [Related]
12. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia.
Stilgenbauer S; Tausch E; Roberts AW; Davids MS; Eichhorst B; Hallek M; Hillmen P; Schneider C; Schetelig J; Böttcher S; Kater AP; Jiang Y; Boyer M; Popovic R; Ghanim MT; Moran M; Sinai WJ; Wang X; Mukherjee N; Chyla B; Wierda WG; Seymour JF
Blood Adv; 2024 Apr; 8(8):1992-2004. PubMed ID: 38290108
[TBL] [Abstract] [Full Text] [Related]
13. Chronic myeloid leukemia with two rare fusion gene transcripts of atypical BCR::ABL: A case report and literature review.
Li Y; Zhang Y; Meng X; Chen S; Wang T; Zhang L; Ma X
Medicine (Baltimore); 2024 Jan; 103(3):e36728. PubMed ID: 38241589
[TBL] [Abstract] [Full Text] [Related]
14. Busulfan with 400 centigray of total body irradiation and higher dose fludarabine: An alternative regimen for hematopoietic stem cell transplantation in pediatric acute lymphoblastic leukemia.
Gharial J; Guilcher G; Truong T; Shah R; Desai S; Rojas-Vasquez M; Kangarloo B; Lewis V
Pediatr Blood Cancer; 2024 Apr; 71(4):e30844. PubMed ID: 38217082
[TBL] [Abstract] [Full Text] [Related]
15. Maintenance therapy for chronic lymphocytic leukaemia.
Lee CH; Wu YY; Huang TC; Lin C; Zou YF; Cheng JC; Chen PH; Jhou HJ; Ho CL
Cochrane Database Syst Rev; 2024 Jan; 1(1):CD013474. PubMed ID: 38174814
[TBL] [Abstract] [Full Text] [Related]
16. Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial.
Zeidan AM; Ando K; Rauzy O; Turgut M; Wang MC; Cairoli R; Hou HA; Kwong YL; Arnan M; Meers S; Pullarkat V; Santini V; Malek K; Kiertsman F; Niolat J; Ramos PM; Menssen HD; Fenaux P; Miyazaki Y; Platzbecker U
Lancet Haematol; 2024 Jan; 11(1):e38-e50. PubMed ID: 38065203
[TBL] [Abstract] [Full Text] [Related]
17. Hypercalcemia associated with interaction between all trans retinoic acid and fluconazole in an acute promyelocytic leukemia and acquired hypoparathyroidism case.
Akman BT; Arıca D; Koca E; Karakuş S
J Oncol Pharm Pract; 2024 Apr; 30(3):605-609. PubMed ID: 37981866
[TBL] [Abstract] [Full Text] [Related]
18. Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Niemann CU; Munir T; Moreno C; Owen C; Follows GA; Benjamini O; Janssens A; Levin MD; Robak T; Simkovic M; Voloshin S; Vorobyev V; Yagci M; Ysebaert L; Qi K; Qi Q; Sinet P; Parisi L; Srinivasan S; Schuier N; Baeten K; Howes A; Caces DB; Kater AP
Lancet Oncol; 2023 Dec; 24(12):1423-1433. PubMed ID: 37944541
[TBL] [Abstract] [Full Text] [Related]
19. Pharmacokinetic Consideration of Venetoclax in Acute Myeloid leukemia Patients: A Potential Candidate for TDM? A Short Communication.
Philippe M; Guitton J; Goutelle S; Thoma Y; Favier B; Chtiba N; Michallet M; Belhabri A
Ther Drug Monit; 2024 Feb; 46(1):127-131. PubMed ID: 37941111
[TBL] [Abstract] [Full Text] [Related]
20. Chemical Inhibitors Targeting the Oncogenic m
Huang Y; Xia W; Dong Z; Yang CG
Acc Chem Res; 2023 Nov; 56(21):3010-3022. PubMed ID: 37889223
[TBL] [Abstract] [Full Text] [Related]
[Next]
